MA31884B1 - Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 - Google Patents
Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3Info
- Publication number
- MA31884B1 MA31884B1 MA32778A MA32778A MA31884B1 MA 31884 B1 MA31884 B1 MA 31884B1 MA 32778 A MA32778 A MA 32778A MA 32778 A MA32778 A MA 32778A MA 31884 B1 MA31884 B1 MA 31884B1
- Authority
- MA
- Morocco
- Prior art keywords
- kiase
- thienopyrimidine
- inhibitors
- mtor kinase
- pyrazolopyrimidine derivatives
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title abstract 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98033207P | 2007-10-16 | 2007-10-16 | |
| US2759508P | 2008-02-11 | 2008-02-11 | |
| PCT/US2008/079940 WO2009052145A1 (en) | 2007-10-16 | 2008-10-15 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31884B1 true MA31884B1 (fr) | 2010-12-01 |
Family
ID=40345078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32778A MA31884B1 (fr) | 2007-10-16 | 2010-04-16 | Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8129371B2 (enExample) |
| EP (1) | EP2212333A1 (enExample) |
| JP (1) | JP2011500702A (enExample) |
| KR (1) | KR20100083170A (enExample) |
| CN (1) | CN101883774A (enExample) |
| AP (1) | AP2010005234A0 (enExample) |
| AR (1) | AR068898A1 (enExample) |
| AU (1) | AU2008312631A1 (enExample) |
| BR (1) | BRPI0817681A2 (enExample) |
| CA (1) | CA2702838A1 (enExample) |
| CL (1) | CL2008003061A1 (enExample) |
| CO (1) | CO6321257A2 (enExample) |
| CR (1) | CR11373A (enExample) |
| DO (1) | DOP2010000118A (enExample) |
| EA (1) | EA201000484A1 (enExample) |
| EC (1) | ECSP10010112A (enExample) |
| IL (1) | IL205109A0 (enExample) |
| MA (1) | MA31884B1 (enExample) |
| MX (1) | MX2010004260A (enExample) |
| NI (1) | NI201000060A (enExample) |
| PA (1) | PA8799101A1 (enExample) |
| PE (1) | PE20091384A1 (enExample) |
| TN (1) | TN2010000171A1 (enExample) |
| TW (1) | TW200922593A (enExample) |
| WO (1) | WO2009052145A1 (enExample) |
| ZA (1) | ZA201003430B (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264819C (en) * | 1996-09-04 | 2010-03-23 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| KR20110046514A (ko) * | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| ME02230B (me) * | 2009-01-08 | 2016-02-20 | Curis Inc | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| EP2419432B9 (en) * | 2009-04-17 | 2016-02-17 | Wyeth LLC | Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| CA2761445A1 (en) * | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20110021515A1 (en) * | 2009-07-24 | 2011-01-27 | Takeda Pharmaceutical Company Limited | Dihyrofuropyrmindine compounds |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| MX2012005463A (es) * | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
| BR112012011147A2 (pt) * | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
| WO2011078795A1 (en) * | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
| WO2011125012A1 (en) | 2010-04-05 | 2011-10-13 | Wyeth Llc | Biomarkers for p13k-driven cancer |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| JP2013544829A (ja) * | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2012099581A1 (en) | 2011-01-19 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Dihydrofuropyrimidine compounds |
| EP2739751A1 (en) | 2011-08-03 | 2014-06-11 | Signal Pharmaceuticals, LLC | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| US9458162B2 (en) * | 2012-01-31 | 2016-10-04 | Nanjing Allgen Pharma Co. Ltd. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
| WO2013152717A1 (zh) * | 2012-04-10 | 2013-10-17 | 上海昀怡健康管理咨询有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| CN103374021B (zh) * | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
| KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
| CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| AU2014254057A1 (en) | 2013-04-17 | 2015-11-05 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| NZ629411A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| KR102242505B1 (ko) | 2013-04-17 | 2021-04-20 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법 |
| ES2944478T3 (es) | 2013-04-17 | 2023-06-21 | Signal Pharm Llc | 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ，エルエルシー | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法 |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| US9745321B2 (en) | 2013-09-30 | 2017-08-29 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| CA2948587C (en) | 2014-05-14 | 2018-07-17 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| CN108358949A (zh) * | 2018-03-01 | 2018-08-03 | 南京法恩化学有限公司 | 一种2，4-二氯噻吩并[3，2-d]嘧啶的制备方法 |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| CN110850012B (zh) * | 2018-08-21 | 2022-07-08 | 四川弘远药业有限公司 | 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法 |
| EP3920911A4 (en) * | 2019-02-06 | 2023-03-08 | Venthera, Inc. | Topical phosphoinositide 3-kinase inhibitors |
| CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN109824701B (zh) * | 2019-03-26 | 2021-08-13 | 武汉工程大学 | 一种吡啶并噻唑类化合物及其制备方法和应用 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3800188A1 (en) | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CN113278015B (zh) * | 2021-05-31 | 2022-05-13 | 云南大学 | 一种荧光探针及其制备方法和应用 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2025201469A1 (zh) * | 2024-03-28 | 2025-10-02 | 励缔(杭州)医药科技有限公司 | 具有mTOR抑制活性的有机化合物及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1186324C (zh) * | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
-
2008
- 2008-10-15 CN CN2008801190434A patent/CN101883774A/zh active Pending
- 2008-10-15 KR KR1020107010683A patent/KR20100083170A/ko not_active Ceased
- 2008-10-15 JP JP2010530074A patent/JP2011500702A/ja not_active Withdrawn
- 2008-10-15 MX MX2010004260A patent/MX2010004260A/es not_active Application Discontinuation
- 2008-10-15 CA CA2702838A patent/CA2702838A1/en not_active Abandoned
- 2008-10-15 AP AP2010005234A patent/AP2010005234A0/xx unknown
- 2008-10-15 EA EA201000484A patent/EA201000484A1/ru unknown
- 2008-10-15 EP EP08839537A patent/EP2212333A1/en not_active Withdrawn
- 2008-10-15 WO PCT/US2008/079940 patent/WO2009052145A1/en not_active Ceased
- 2008-10-15 US US12/251,712 patent/US8129371B2/en not_active Expired - Fee Related
- 2008-10-15 AU AU2008312631A patent/AU2008312631A1/en not_active Abandoned
- 2008-10-15 BR BRPI0817681 patent/BRPI0817681A2/pt not_active Application Discontinuation
- 2008-10-16 AR ARP080104520A patent/AR068898A1/es unknown
- 2008-10-16 PA PA20088799101A patent/PA8799101A1/es unknown
- 2008-10-16 PE PE2008001780A patent/PE20091384A1/es not_active Application Discontinuation
- 2008-10-16 CL CL2008003061A patent/CL2008003061A1/es unknown
- 2008-10-16 TW TW097139718A patent/TW200922593A/zh unknown
-
2010
- 2010-04-15 NI NI201000060A patent/NI201000060A/es unknown
- 2010-04-15 IL IL205109A patent/IL205109A0/en unknown
- 2010-04-15 CR CR11373A patent/CR11373A/es not_active Application Discontinuation
- 2010-04-16 MA MA32778A patent/MA31884B1/fr unknown
- 2010-04-16 TN TN2010000171A patent/TN2010000171A1/fr unknown
- 2010-04-16 DO DO2010000118A patent/DOP2010000118A/es unknown
- 2010-04-16 EC EC2010010112A patent/ECSP10010112A/es unknown
- 2010-04-20 CO CO10046199A patent/CO6321257A2/es not_active Application Discontinuation
- 2010-05-14 ZA ZA2010/03430A patent/ZA201003430B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100083170A (ko) | 2010-07-21 |
| JP2011500702A (ja) | 2011-01-06 |
| CO6321257A2 (es) | 2011-09-20 |
| ZA201003430B (en) | 2011-02-23 |
| ECSP10010112A (es) | 2010-08-31 |
| EA201000484A1 (ru) | 2010-12-30 |
| TW200922593A (en) | 2009-06-01 |
| NI201000060A (es) | 2010-10-04 |
| EP2212333A1 (en) | 2010-08-04 |
| MX2010004260A (es) | 2010-04-30 |
| AP2010005234A0 (en) | 2010-04-30 |
| AU2008312631A1 (en) | 2009-04-23 |
| WO2009052145A1 (en) | 2009-04-23 |
| IL205109A0 (en) | 2010-11-30 |
| BRPI0817681A2 (pt) | 2015-04-14 |
| US20090098086A1 (en) | 2009-04-16 |
| PA8799101A1 (es) | 2009-05-15 |
| TN2010000171A1 (fr) | 2011-11-11 |
| DOP2010000118A (es) | 2010-06-30 |
| CA2702838A1 (en) | 2009-04-23 |
| CN101883774A (zh) | 2010-11-10 |
| CR11373A (es) | 2010-05-03 |
| AR068898A1 (es) | 2009-12-16 |
| CL2008003061A1 (es) | 2009-01-09 |
| US8129371B2 (en) | 2012-03-06 |
| PE20091384A1 (es) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31884B1 (fr) | Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 | |
| MA32615B1 (fr) | Inhibiteurs de cmet | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| WO2006105127A8 (en) | Hydroxysteroid dehydrogenase inhibitors | |
| WO2006066109A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
| MA31151B1 (fr) | Inhibiteurs de mapk/erk kinase | |
| PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| EA200870292A1 (ru) | Соединения на основе имидазола, композиции, содержащие их, и способы их применения | |
| MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| WO2008007211A8 (en) | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds | |
| MY146989A (en) | Kinase inhibitors | |
| EA200700225A1 (ru) | Аналоги тетрапептида | |
| WO2007028135A3 (en) | Imidazopyridine compounds | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| TW200621753A (en) | Pyrimidinylimidazoles and methods of making and using the same | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| WO2007103508A3 (en) | Ligands for nematode nuclear receptors and uses thereof | |
| EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
| MA32343B1 (fr) | Pyrimidyle cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt | |
| WO2008054956A3 (en) | Kinase inhibitors | |
| ATE380816T1 (de) | Substituierte imidazopyrimidine zur prävention und behandlung von krebs |